Efficacy of Soluble Dexamethasone in Refractory Sciatica (Dexhia)

January 31, 2024 updated by: Nantes University Hospital

Efficacy of Soluble Dexamethasone by Echo-guided Infiltration Through the Sacrococcygeal Hiatus in Refractory Sciatica: a Prospective Randomised Double-blind Study Versus Placebo

This is a phase 3 prospective randomised double-blind study versus placebo, measuring the efficacy of soluble Dexamethasone by echo-guided infiltrations through the sacro-coccygeal hiatus in intractable sciatica

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Injection of 4ml of Dexamethasone Phosphate Soluble or 4ml of saline solution depending on the randomisation arm

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
109

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • France
      • Nantes, France, 44093
        • Nantes university hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with sciatica of disc origin (radio-clinical concordance on MRI or CT) postero-lateral
  • Duration of evolution greater than 3 weeks despite analgesic / AINS treatment, and less than 3 months
  • EVA sciatica pain > 4/10
  • Oswestry 30 at inclusion
  • Patient aged 18 years and older
  • Patient affiliated to a social security scheme
  • Patient able to understand the protocol and having signed an informed consent
  • Patient with an indication for corticosteroid infiltration in the context of their pathology

Criteria for non-inclusion

  • Signs or risks of infection, in particular signs of virosis
  • Poor local skin condition
  • Anticoagulation with VKA or anti-Xa, or haemorrhagic disease
  • Neurological deficit < 3/5 or signs of cauda equina irritation
  • Tarlov's cyst or low dural sac below week 4
  • Hypersensitivity to Lidocaine, Dexamethasone, or any of its excipients
  • Infiltration of the spine within the previous 3 months
  • Patient with bilateral sciatica
  • Patient with sciatica of osteoarthritic origin
  • Patients with chronic respiratory insufficiency
  • Pregnant or breastfeeding women or women refusing effective contraception until M3
  • Patient deprived of liberty or under legal protection (guardianship or curatorship)
  • Patient under court protection
  • Patients participating in another clinical research protocol involving a drug or medical device
  • Patients unable to follow the protocol, as judged by the investigator
  • Patient refusing to participate in the study
  • Patient with clinically narrowed lumbar canal
  • Patient with polyneuropathy or myelopathy
  • Patient with sequelae of neuropathic pain

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: group A
HSC one injection of 4 mL soluble Dexamethasone phosphate (16 mg) (equivalent to 100 mg Prednisone), followed by up to 16 mL saline (depending on tolerance)
Drug: Dexamethasone phosphate
HSC injection of 4mL
Placebo Comparator: group B
HSC one injection of 4mL of saline and then up to 16 mL of saline (depending on tolerance)
Drug: Dexamethasone phosphate
HSC injection of 4mL

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Effectiveness assessed by classical global algo-functional index: OSWESTRY
Time Frame: Week 3
Week 3

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Value of Eva scale for evaluated effectiveness on lower back pain
Time Frame: Month 6
Month 6
Value of Eva scale for evaluated effectiveness on lower back pain
Time Frame: Week 1
Week 1
Value of Eva scale for evaluated effectiveness on lower back pain
Time Frame: Week 3
Week 3
Value of Eva scale for evaluated effectiveness on lower back pain
Time Frame: Week 6
Week 6
Value of Eva scale for evaluated effectiveness on lower back pain
Time Frame: Month 3
Month 3
Value of Eva scale for evaluated effectiveness on sciatic pain
Time Frame: Week 1
Week 1
Value of Eva scale for evaluated effectiveness on sciatic pain
Time Frame: Week 3
Week 3
Value of Eva scale for evaluated effectiveness on sciatic pain
Time Frame: Week 6
Week 6
Value of Eva scale for evaluated effectiveness on sciatic pain
Time Frame: Month 6
Month 6
Number of days off work
Time Frame: Month 6
Month 6
Value of score to scale Oswestry
Time Frame: Month 6
Month 6
Value of score to scale Oswestry
Time Frame: Week 1
Week 1
Value of score to scale Oswestry
Time Frame: Week 6
Week 6
Value of score to scale Oswestry
Time Frame: Month 3
Month 3
Value of score to SF36 self questionnaires
Time Frame: Month 6
Month 6
Value of score to SF36 self questionnaires
Time Frame: Week 1
Week 1
Value of score to SF36 self questionnaires
Time Frame: Week 3
Week 3
Value of score to SF36 self questionnaires
Time Frame: Week 6
Week 6
Value of score to SF36 self questionnaires
Time Frame: Month 3
Month 3
Percentage of second injections required
Time Frame: Month 6
Month 6
Number of patients undergoing secondary surgery
Time Frame: Month 6
Month 6
Result of Clinical parameters
Time Frame: week 3
week 3
Result of Imaging parameters
Time Frame: week 3
week 3
Number of secondary effects
Time Frame: Month 6
Month 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Nantes University Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Maugars, Nantes university hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 16, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 15, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 15, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 4, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 4, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 11, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 1, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 31, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RC21_0148

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings